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Background: Inherited thrombocytopenias (IT) are a heterogeneous group of rare diseases characterized by a reduced
number of blood platelets. The frequency of IT is probably underestimated because of diagnostic difficulties and because
not all the existing forms have as yet been identified, with some patients remaining without a definitive diagnosis. Exome
Sequencing has made possible the identification of almost all variants in the coding regions of protein-coding genes,
thereby providing the opportunity to identify the disease causing gene in a number of patients with indefinite diagnoses,
specifically in consanguineous families.
Case presentation: Familial thrombocytopenia with small size platelets was present in several members of a highly
consanguineous family from Northern Iraq. Genotyping of all affected, their unaffected siblings and parents, followed by
exome sequencing revealed a strong candidate loss of function variant in a homozygous state: a frameshift mutation in
the FYB gene. The protein encoded by this gene is known to be a cytosolic adaptor molecule expressed by T, natural
killer (NK), myeloid cells and platelets, and is involved in platelet activation and controls the expression of interleukin-2.
Knock-out mice were reported to show isolated thrombocytopenia.
Conclusion: Inherited thrombocytopenias differ in their presentation, associated features, and molecular etiologies. An
accurate diagnosis is needed to provide appropriate management as well as counseling for the individuals and their
family members. Exome sequencing may become a first diagnostic tool to identify the molecular basis of undiagnosed
familial IT. In this report, the clinical evaluation combined with the power and efficiency of genomic analysis defined the
FYB gene as the possible underlying cause of autosomal recessive thrombocytopenia with small platelet size. This is the
first report linking pathogenic variants in FYB and thrombocytopenia in humans.
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Inherited thrombocytopenias (IT) are a heterogeneous
group of rare diseases characterized by a reduced number
of blood platelets. Several genes coding for membrane
glycoproteins, cytoskeleton components and intracellular
signaling pathways, as well as transcription factors, have
been identified as causative in IT, though the pathophysi-
ology remains unknown in some instances [1]. The
frequency of IT is probably underestimated because of
diagnostic difficulties and because not all the existing* Correspondence: hananhamamy@yahoo.com
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unless otherwise stated.forms have as yet been identified, with some patients
remaining without a definitive diagnosis [2]. In the last
5 years, nine new genes whose mutations are responsible
for thrombocytopenia have been identified. To date, ITs
encompass 20 forms caused by mutations of 21 genes with
only four syndromes reported to have an autosomal reces-
sive mode of inheritance [3].
High Throughput Sequencing (HTS) has made possible
the identification of almost all variants in the coding
regions of protein-coding genes, thereby providing the
opportunity to identify the disease causing gene in a
number of patients with indefinite diagnoses, specifically
in consanguineous families [4]. Exome sequencing may
become a first diagnostic tool to identify the molecular
basis of rare IT [5] as exemplified by the report defining. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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topenia [6].
In this report, we describe a novel autosomal recessive
bleeding disorder likely caused by a mutation in the FYB
gene. FYN binding protein (FYB-120/130), also known
as FYB, ADAP (Adhesion- and Degranulation-promoting
Adapter Protein), and SLAP-130 (SLP-76-associated phos-
phoprotein of 130 kDa) and encoded by the FYB gene is a
cytosolic adaptor molecule expressed by T , natural killer
(NK) and myeloid cells and by platelets [7]. This gene
is recognized to affect murine T cells and platelet func-
tion but has not yet been linked to a human disease.
The autosomal recessive bleeding phenotype seen in several
members of this highly consanguineous family included
petechial rash, mild epistaxis and thrombocytopenia with
some decrease in platelet volume. These clinical findings,
together with the results of exome sequencing pointed to
only one strong candidate gene, the FYB gene, known to
affect platelet function and causes mild thrombocytopenia
in knockout mice [8].
Case presentation
Clinical data
Figure 1A shows the pedigree of the highly consanguin-
eous family originating from Northern Iraq. The first pro-
band of the family (IV: 5, Figure 1A) presented in 2003 at
the age of 1.5 years with isolated generalized petechial
rashes. Investigations revealed normal Hb concentration
(128 g/L) and leucocyte count (11.0 ? 10 9/L), with normalFigure 1 Pedigree (A) and Sanger sequencing (B). A: Family ? s pedigre
B: The segregation of the variant was confirmed in the twelve family membe
proband (IV: 5) and her father (III: 5) in the forward (F) and reverse (R) orientat
The letters underneath are showing the reference sequence. In IV: 5 s seq
in homozygosity.differential count and morphology. Platelet count was low
at 40 ? 10 9/L and the platelets were of small size with
mean platelets volume (MPV) of 6.0 fL [Normal range is
7.0-11.0 fL]. No giant platelets were identified. Bone mar-
row (BM) aspiration revealed a normocellular marrow,
with normal number of megakaryocytes and no abnormal
cells. The patient was treated with steroid therapy for vari-
ous periods and on different occasions for the following
5 years but without any remarkable response (platelets
varied between 20 ? 45 ?10 9/L throughout this period).
On re-evaluation in 2008 the patient, showed no gross
physical anomalies, no hepatosplenomegaly and no lymph-
adenopathy. Her physical development was normal, with
no skin lesions. Hematologic investigations were similar
(Hb: 127 g/L and WBC: 10 ? 10 9/L with normal morph-
ology, platelet count of 25 ? 10 9/L) and again low MPV
(5.8 fL). Aspiration showed active BM with normal number
of megakaryocytes. The patient was treated with azathio-
prine with partial response for about 2 months followed by
no response and so the drug was discontinued.
In 2009, her younger sister (IV: 6, Figure 1A), 4 years
old at that time, developed a similar condition of isolated
petechial rash with mild epistaxis. Abdominal ultrasound
did not show any abnormalities or hepatosplenomegaly.
Blood counts showed a Hb of 126 g/L and WBC of 11.3 ?
109/L (with normal differential), platelet count was 32 ?
109/L, no giant platelets were seen and MPV was 5.4 fL.
Bone Marrow aspiration showed normal number of
megakaryocytes.e. DNA samples were available from individuals marked with arrows.
rs. The figure shows the forward and reverse strand chromatogram of the
ion. In the III: 5 s sequences the frameshift is evident in both orientations.
uences no frameshift is observed as expected since the variation is
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a 5 year old male, developed a similar clinical picture of
petechial rash as IV:5 and IV:6 with mild mucosal haemor-
rhage. Blood counts showed a Hb of 127 g/L, WBC 8.2 ?
109/L (normal differential and morphology), and platelets
count of 34 ? 10 9/L with an MPV of 6.2 fL. BM aspiration
showed a normocellular marrow with normal number of
megakaryocytes.
None of the patients had immune defects, unusual
infections or growth abnormalities and the hematologic
indices in the parents of the three patients showed no
abnormalities
Since all three affected members in this family were
born to consanguineous parents and showed isolated
thrombocytopenia with no giant platelets, the most
probable diagnosis was familial or autosomal recessive
thrombocytopenia. The family provided written informed
consent for the genetic analyses performed.Investigations
Full blood counts were performed using a hematology
analyzer (Beckman Coulter, USA), calibrated daily by qual-
ity assurance material provided by the manufacturers.
Films for peripheral blood and marrow were stained by
Leishman stain for morphology. DNA was extracted from
EDTA anticoagulated blood by phenol chloroform method
from affected and unaffected family members (marked
with arrows in Figure 1).
Genotyping and exome sequencing were performed in
the Genetic Medicine laboratory at Geneva University.
DNA samples were genotyped using the HumanOmniEx-
press Bead Chip by Illumina Inc? (San Diego, CA, USA).
After filtering for quality, the results were used in order to
define the Runs of Homozygosity (ROH) using PLINK [9].
We defined as ROH any region of the genome with 50
consecutive SNPs irrespective of the genomic size, allow-
ing for one mismatch.
The exome of one affected individual (IV: 5, Figure 1A)
was captured using the SureSelect Human All Exons v3
reagents (Agilent Inc?). Sequencing was performed in an
Illumina HiSeq 2000 instrument. The exome library was
indexed, separated into two equal halves and sequenced
in two different lanesand the raw results analyzed as
described in Makrythanasis et al., [4]. The ROH coordi-
nates, the genotypes and the exome results were processed
using an inhouse algorithm (CATCH v1.1, unpublished).
CATCH takes additionally into account the family infor-
mation and assigns every variant to a different class
according to how well it respects the segregation of the
ROH. The filters used were homozygous exonic and spli-
cing variants (?6 bp from the intron ? exon junction) with
a minimum allele frequency less than 0.02 in public
(dbSNP, 1000 genomes, ESP) and the local database. Onlyvariants found inside ROH and respecting the segregation
were kept for further analysis [4].
ROH calculations from the parents revealed in average
70.25 ROH with average size 1.5Mbp and total average
length per individual 106Mbp, while in the children the
equivalent average values were 80.125 ROH with average
size 3.6Mbp and total average length per individual
297Mbp. The increase of the total size of the ROH between
the parents and the children is as expected in cases of
consanguineous families.
After exome sequencing 91.32% of the RefSeq was cov-
ered at least 8x, identifying 19,272 exonic variants of high
quality, 9,786 of which were synonymous (50.78%). 8,713
(45.21%) were missense, 56 (0.29%) were nonsense and
326 were indels (1.69%). These numbers are in accordance
to what is expected for the attained depth and coverage
and the exome capture kit that was used.
Only one variant was reported by CATCH respecting
the selection criteria and the family segregation (Figure 2),
a 2 bp deletion which introduces a stop codon in the FYB
gene (NM_001465.3:c.1385_1386del: p.(Tyr462*)). Sanger
sequencing (Figure 1B) has confirmed the variant in IV:5
and have shown that the other two affected members
(IV:3 and IV:6) were also homozygous. As expected the 4
parents were heterozygous for the variant and all the non-
affected siblings for whom we had samples (marked as
arrows in Figure 1A) were also heterozygous for the
variant. Figure 2 focuses on the ROHs identified in
chromosome 5 that contains FYB. The different indi-
viduals are shown on top. Parents are noted with blue,
affected siblings with orange and unaffected siblings
with green. The position of FYB is noted in red. The
identified common ROH spanned positions 33622158
to 39735991. In total 20 variants have been found inside
this area. 19 of them were excluded due to high reported
minimum allele frequency ranging from 0.14 to 0.98. The
only novel variant was the one found in FYB.
The study was approved by the Bioethics Committee
of the University Hospitals of Geneva (Protocol number:
CER 11 ? 036).
Inherited thrombocytopenia could be classified accord-
ing to platelet size, into those with small (MPV < 7 fL),
normal (MPV = 7 ? 11 fL) or large/giant (MPV >11 fL)
platelets [10]. A number of syndromes of inherited
thrombocytopenia with normal and small sized platelets have
been described, among which only two syndromes with
autosomal recessive mode of inheritance are known.
These include congenital amegakaryocytic thrombocytopenia
(CAMT, OMIM 604498), and thrombocytopenia with
absent radii (TAR, OMIM 274000).
CAMT is characterized by very severe thrombocyto-
penia giving rise to the risk of life-threatening hemor-
rhages. The disease progresses to bone marrow aplasia
within the first years of life resulting in death if patients
Figure 2 ROHs identified in chromosome 5 that contains FYB.
The different individuals are shown on top. Parents are noted with
blue, affected siblings with orange and unaffected siblings with
green. The position of FYB is noted in red. The identified common
ROH spanned positions 33622158 to 39735991. In total 20 variants
have been found inside this area. 19 of them were excluded due to
high reported minimum allele frequency ranging from 0.14 to 0.98.
The only novel variant was the one found in FYB.
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CAMT was excluded as the diagnosis in this family
because of the presence of normal number of megakaryo-
cytes in BM in all affected and no pathogenic variant was
identified in this gene by exome sequencing. Thrombo-
cytopenia with absent radii (TAR) belongs to the group of
inherited hypomegakaryocytic thrombocytopenias associ-
ated with skeletal defects [11]. In our family TAR syn-
drome was excluded because there were no reductions in
marrow megakaryoytes and there were no absent radii in
any of the patients.
The two syndromes with thrombocytopenia and low
MPV, Wiskott-Aldrich syndrome (OMIM 301000) and
X-linked thrombocytopenia (OMIM 313900) were not
considered in the differential diagnosis for this family
because of absence of eczema and repeated infection and
because both sexes are affected pointing more to an auto-
somal recessive mode of inheritance. Most other inherited
thrombocytopenias have an autosomal dominant mode of
inheritance and high MPV and so were excluded from the
differential diagnosis in this family.
The results of exome sequencing identified only one
candidate gene (FYB, MIM 602731), where homozygouspathogenic variants were present in all affected but
none of the non-affected members tested. Parents of af-
fected and all unaffected siblings (marked in arrows in
Figure 1A) were heterozygous for the variant. Hematologic
investigations of all carriers showed normal results. No
human disorder is currently linked to FYB.
Structurally, human and murine FYB are conserved,
with some divergence found mostly near the N-terminal
part of the molecule, a region with no apparent homology
to other proteins. Conservation is most apparent in the
potential functional motifs such as the SH3-like domain
and the putative nuclear localization motifs, suggesting
that FYB may localize to both the cytoplasm and nucleus.
Fyb knockout mice (−/−) are viable, fertile, and show
normal growth. Hematopoietic cellularity is normal with
the exception of modest significant thrombocytopenia, a
50% reduction in splenic T cells, and mildly decreased
thymocyte number [8]. They also, have enlarged spleens
as compared with wild-type animals. This may reflect
increased removal of platelets from the circulation [12].
Among Fyb−/− mice, 61.8% show rebleeding from tail
wounds within 1 minute of initial arrest in comparison to
21.9% of Fyb+/+ mice. Plasma from Fyb−/− mice showed
normal thrombin and activated partial thromoboplastin
times which may suggest that the higher rebleeding rate is
due to platelet dysfunction [13]. Fyb has a role in αIIbβ3
mediated platelet mechanotransduction that promotes
F-actin assembly and enables platelet spreading and
thrombus stabilization under fluid shear stress [14]. The
Fyb knockout mice (−/−) showed thrombocytopenia and
normal growth as did the patients with the FYB patho-
genic variant, but also showed splenomegaly which was
not detected in the human phenotype In light of this
evidence we consider FYB as the candidate for the
thrombocytopenia that was observed in our patients.Conclusion
In this report, the clinical evaluation combined with the
power and efficiency of genomic analysis defined the
FYB gene as the possible underlying cause of autosomal
recessive thrombocytopenia with small platelet size. The
role of the FYB gene in causing thrombocytopenia in
human will be established when other families with un-
diagnosed inherited thrombocytopenia show pathogenic
variants in this gene. Further studies are needed to eluci-
date the molecular pathophysiology of this disease and
additional families are needed for the full description of
the phenotypic manifestations.Consent
We confirm that the patient/s (families) have given their
consent for the publication of this case report and any
accompanying images.
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